ANVISA introduced updates affecting COVID-19 vaccine regulatory handling and revised the classification criteria for low-risk medicines. These changes aim to streamline regulatory oversight, optimize risk-based categorization, and improve efficiency in the evaluation and monitoring of lower-risk pharmaceutical products.
Select Mandate HA
Select Mandate Function